Head-to-Head-Therapiestudien zur rheumatoiden Arthritis-Reference-Cited by-同舟云学术

Head-to-Head-Therapiestudien zur rheumatoiden Arthritis

Published:2024-06-03 Issue: Volume: Page:
ISSN:0340-1855
Container-title:Zeitschrift für Rheumatologie
language:de
Short-container-title:Z Rheumatol

Author:

Ernst Diana,Krüger Klaus,Witte Torsten

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00393-024-01517-8.pdf

Reference25 articles.

1. Breedveld FC, Weisman MH, Kavanaugh AF et al (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37

2. Burmester GR, Lin Y, Patel R et al (2017) Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 76:840–847

3. Combe B, Kivitz A, Tanaka Y et al (2021) Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis 80:848–858

4. Emery P, Breedveld FC, Lemmel EM et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Baillieres Clin Rheumatol 39:655–665

5. Emery P, Fleischmann RM, Moreland LW et al (2009) Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60:2272–2283